QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=3C0722236A41C6A3133E61589B69E909;jsessionid=53792359AD60CFBAC92BD58A19D86323;jsessionid=E3AEF34EBEEFB1A6821C7D5EB342E6BD;jsessionid=52467F3FDA948E71252DB94936392BBA (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. Abnormal open states patterns in the ATXN2 DNA sequence depends on the CAG repeats length.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=3C0722236A41C6A3133E61589B69E909;jsessionid=53792359AD60CFBAC92BD58A19D86323;jsessionid=E3AEF34EBEEFB1A6821C7D5EB342E6BD;jsessionid=52467F3FDA948E71252DB94936392BBA